Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAMARACK
2022-501078-20-00Phase 2Completed
- Sponsor
- MacroGenics
- Start
- Feb 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
Phase 2, randomised, open-label trial of vobramitamab duocarmazine in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by MacroGenics. Primary endpoint: Radiographic progression-free survival (rPFS) per PCWG3 criteria. Started Feb 2023; status: completed.
02
Drugs
vobramitamab duocarmazine
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2022-501078-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501078-20-00.